Rationale: IFN-g release assays (IGRAs) are alternatives to tuberculin skin testing (TST) for diagnosis of latent tuberculosis infection. Limited data suggest IGRAs may not perform well for serial testing of healthcare workers (HCWs).
At a Glance Commentary
Scientific Knowledge on the Subject: IFN-g release assays (IGRAs) are alternatives to tuberculosis skin testing for the diagnosis of latent tuberculosis infection. Healthcare workers (HCWs) in the United States undergo periodic screening for evidence of tuberculosis (TB) infection; however, little is known about the performance of IGRAs in serial testing of HCWs in low-incidence settings.
What This Study Adds to the Field: This large multicenter study of HCWs undergoing TB screening at four healthcare institutions in the United States documented that IGRAs are associated with significantly higher conversion rates than the tuberculin skin test and that these IGRA conversions appear to be falsely positive. Furthermore, there is significant short-and longterm variability of IGRA results. On the basis of the results of this study, current HCW screening strategies should be reexamined.
Diagnosis and treatment of latent tuberculosis infection (LTBI) are important components of tuberculosis control in the United States (1) . Healthcare workers (HCWs) are an important group for targeted LTBI testing (2) . Until recently, the only method for detecting LTBI was the tuberculin skin test (TST). The TST has limitations including low sensitivity, a subjective end point, and results that can be influenced by prior bacillus CalmetteGuérin (BCG) vaccination or infection with nontuberculous mycobacteria (3, 4) . Despite these limitations, annual TST conversion rates have been below 1% in most U.S. hospitals after implementation of measures to limit nosocomial TB transmission (5) .
IFN-g release assays (IGRAs), in vitro blood tests that detect immunologic responses to Mycobacterium tuberculosis complex antigens, have potential for improving LTBI testing (6, 7) . IGRAs require one patient-provider interaction to obtain results, which can be available within 1 day and are not affected by prior BCG vaccination (8, 9) . The Centers for Disease Control and Prevention (CDC, Atlanta, GA) has issued guidance that, for detection of TB infection, IGRAs may be used in place of a TST, and IGRAs are preferred for testing BCG-vaccinated persons (6) . The QuantiFERON-TB Gold In-Tube (QFT-GIT; Cellestis [a Qiagen company], Valencia, CA) and T-SPOT.TB (T-SPOT; Oxford Immunotec Ltd., Abingdon, UK) tests are U.S. Food and Drug Administration-approved IGRAs for diagnosing TB infection. IGRAs perform well for detection of TB infection among contacts of individuals with active pulmonary TB (10, 11) . However, with the introduction of IGRAs into clinical practice, a broader population is being tested including individuals undergoing serial testing in the absence of known exposure. Published experience, much of which is from settings of routine clinical use with potential selection bias with respect to individuals selected for testing or repeat testing, indicates unexpectedly high rates of IGRA positivity, conversion (change from a negative to positive), and reversion (change from positive to negative) (12) (13) (14) (15) (16) (17) .
The objectives of this multicenter study conducted in U.S. HCWs undergoing serial testing were to determine the prevalence of positive results for TST, QFT-GIT, and T-SPOT at baseline, the frequencies and correlates of test conversion during followup, IGRA variability over short time intervals during which intervening TB exposure was unlikely, and the impact of a recent TST on IGRA results. Some of the results of these studies have been previously reported in the form of abstracts (18) (19) (20) (21) .
Methods
This was a cross-sectional study with longitudinal follow-up performed between February 2008 and March 2011 at sites in Denver, Colorado; Houston, Texas; Baltimore, Maryland; and New York City, New York (see the online supplement). Ethics committees at the CDC and each site approved the study. Participants gave written informed consent.
Population
An HCW was defined as anyone working in a healthcare setting, regardless of direct patient contact. Inclusion criteria included age equal to or greater than 18 years and HCW undergoing occupational screening for TB. Exclusion criteria included current or prior TB disease, previous anaphylaxis to TST reagents, and TST within the previous 6 months.
Study Schedule
At baseline a structured interview was conducted to collect information about age, self-reported race/ethnicity, occupation, work setting, place of birth and residence, travel, TB exposures, medical history, prior LTBI tests and treatment, and BCG vaccination. One 8-ml or two 4-ml BD Vacutainer CPT cell preparation tubes with sodium citrate (BD Diagnostics, Franklin, NJ) were filled with blood for the T-SPOT assay, and then one each of the QFT-GIT nil control, TB antigens, and mitogen control tubes were filled. Tubes were transported to designated on-site laboratories within 8 hours. TST was performed immediately after phlebotomy. Participants with a negative initial TST underwent another TST within 1-3 weeks ("two-step TST") if they had no documented prestudy TST, the most recent negative TST was more than 13 months before enrollment, or they reported a prior positive TST but were unable to provide documentation of the result. Follow-up visits were at 6, 12, and 18 months after enrollment. At each visit a structured interview, phlebotomy for IGRAs, and single TST were performed (Figure 1 ). Participants with a positive study TST were asked to undergo repeat TST testing; however, they were informed of the potential risk of subsequent tuberculin testing, and were allowed to opt out of TST testing at subsequent study visits (22, 23) .
Substudies of IGRA Variability
Short-term IGRA variability was assessed in a subset of participants by drawing two sets of tubes 2 weeks apart without an intervening TST or likely TB exposure ("repeatability"), and by drawing two sets of tubes during a single blood draw ("reproducibility"). We included consecutive participants whose baseline TST, QFT-GIT, and T-SPOT were concordant negative or concordant positive.
The laboratory procedure for QFT-GIT was modified midway through the parent study to include repeat ELISA testing of stimulated plasmas for all positive tests after higher than expected conversion rates were noted (see the online supplement). The technical requirements of T-SPOT did not allow a similar assessment.
Impact of TST on IGRA Results ("Boosting" Substudy)
To assess whether a recent prior TST affects IGRA results, repeat IGRA testing was performed 7-21 days after baseline testing in a subset of participants who had baseline negative IGRAs (Figure 1 ). Figure 1 (1).
QFT-GIT and T-SPOT. Tests were performed and interpreted per the manufacturers' package inserts ( Figure 1 ) (24, 25) . For QFT-GIT, stimulated plasma samples were tested immediately or stored at 2-8 8 C for up to 2 weeks before testing (24) . Spot-forming cells were visualized with a magnifying glass or suitable microscope and enumerated.
Definitions IGRA "reversion" was defined as a baseline positive test with a subsequent negative test of the same type at one or more of the follow-up visits. IGRA "conversion" was considered to occur if the baseline test was negative (or borderline for T-SPOT) and a subsequent test of that type was positive at one or more of the 6-monthly study visits ( Figure 1 ). TST "conversion" was considered to occur if the baseline TST was classified as negative and any subsequent 6-monthly study TST showed an increase in reaction size by at least 10 mm as recommended by the American Thoracic Society and Centers for Disease Control and Prevention (1). Conversions were categorized as "stable" (change from negative to positive, followed by a positive result on the next 6-monthly follow-up) or "transient" (change from negative to positive, followed by a negative test on the next 6-monthly follow-up). IGRA boosting was defined as a qualitative change from baseline negative to positive on testing 7-21 days later.
Statistics and Analysis
The k coefficient was used for agreement among categorical measures. Independent proportions were compared by two-proportion z-test; dependent proportions were compared by McNemar's test. The Holm-Bonferroni method (26) was used to account for multiple comparisons. The t test was used to compare mean changes in IGRA responses. Results from reproducibility and repeatability substudies were used to assess within-subject variability of continuous IGRA responses. Linear mixed-effects models were fitted to T-SPOT spot counts and to logged QFT-GIT responses (TB antigen minus nil, with QFT-GIT values , 0.1 excluded); models were fitted assuming normal distributions, which was confirmed by residual plots. The estimated within-subject standard deviation and intraclass correlation coefficient were calculated. Participants initiated on LTBI treatment during the study were excluded from analyses of reversion and QFT-GIT reruns. For analyses of conversion and reversion, missing test results (missed time points) were considered noninformative and borderline T-SPOTs were included with the negatives. A P value less than 0.05 was considered statistically significant; all testing was two-sided. Statistical calculations were performed with SAS 9.2 (SAS Institute Inc., Cary, NC); spaghetti plots and random effects modeling were performed in Stata 10.0 (StataCorp, College Station, TX).
Results

Study Population
Among 2,767 individuals screened, 86 (3.1%) were ineligible; 2,563 (95.6%) of the 2,681 eligible individuals participated in the study ( Figure 2 ). Among 2,563 enrolled participants, 2,495 (97.3%) completed baseline testing and 2,122 (82.8%) completed follow-up (Table 1 and Figure 2 ) over the study period of February 2008 to March 2011. Among 2,495 participants who completed baseline testing, 1,875 (75.2%) were female and 2,067 (82.8%) were U.S. born; 428 (17.2%) were born outside the United States, including 291 from high TB burden countries (27). Of the 2,495 participants, 224 (9.0%) reported prior BCG vaccination. Seventy-seven participants with prior LTBI treatment were excluded from analyses, as this group does not typically undergo subsequent LTBI testing. During the study, 11 participants reported starting LTBI treatment based on study positive TST results; no participant was treated solely on the basis of a positive IGRA and none were diagnosed with active TB. Table 2 shows baseline results by test for the main analysis group, stratified by prior TST history. The proportion of participants with a baseline positive test overall was 125 of 2,418 (5.2%) by TST, 118 of 2,418 (4.9%) by QFT-GIT (P = 0.64 vs. TST), and144 of 2,418 (6.0%) by T-SPOT (P = 0.10 vs. TST). Among HCWs routinely screened by occupational health programs (i.e., no prior positive test or TB treatment), a baseline positive test was seen in 40 of 2,263 (1.8%) by TST, 85 of 2,263 (3.8%) by QFT-GIT (P , 0.001 vs. TST), and 113 of 2,263 (5.0%) by T-SPOT (P , 0.001 vs. TST). A borderline T-SPOT occurred in 74 of 2,418 (3.1%), including 60 of 74 (81.1%) with negative TST and QFT-GIT. Overall, 1,968 of 2,418 (81.4%) participants were negative by all three tests, 47 (1.9%) were positive by QFT only, 85 (3.5%) were positive by T-SPOT only, and 33 of 2,418 (1.4%) were positive by all three tests (triple positives) (see Table E1 in the online supplement). We compared the quantitative results at baseline for the 33 participants with triplepositive results and, thus, most likely to have true TB infection, with those that were positive on only one or two tests. The differences in median TST results for triple positives (15 mm) compared with TSTpositive only (16 mm) or dual positive (TST and one IGRA, 19 mm) were minimal and not likely to be clinically meaningful. Median values for QFT and T-SPOT were higher for triple positives than single or dual positives (Table E2 ). Agreement and k values, respectively, were 93.2% and 0.31 There was variation in test results by study site, in part due to the inability to enroll participants with a prior positive TST at the New York site (Table E3) : The proportion of participants with a baseline positive TST, QFT-GIT, or T-SPOT ranged from 1.0 to 11%, 1.2 to 6.4%, and 1.2 to 10.4%, respectively. There was also variation in the frequency of indeterminate/invalid and failed test results. With QFT-GIT, the proportion of indeterminate tests varied from 0.6 to 3.3%. The proportion of T-SPOT results that were invalid varied from 0.7 to 3.7% and the proportion of failed tests varied from 3.0 to 4.8%.
Baseline Testing
Among 214 participants who reported prior BCG vaccination, 124 (57.9%) were negative on all three tests, 15 (7.0%) were positive on all three tests, 58 (27.1%) had only a positive TST, and 17 (7.9%) had other combinations of results. A baseline positive TST with negative IGRAs was associated with BCG vaccination (odds ratio [OR]: 33.4; 95% CI: 20.3, 57.0 vs. no BCG) and did not differ when stratified by place of birth (U.S.-born or foreign-born).
Baseline Test Reversion
Of 125 participants with a baseline positive TST, 54 (43%) received a repeat TST, and 29 of 54 (53.7%) reverted to negative. Comparatively, 67 of 118 (56.8%) with QFT-GIT, and 92 of 144 (63.9%) with T-SPOT, reverted (P = 1.000 for QFT-GIT vs. TST, P = 0.773 for T-SPOT vs. TST, and P = 0.228 for QFT-GIT vs. T-SPOT). The limited numbers of participants with TST reversion did not allow an analysis of factors associated with reversion. Work or social contact with a person who had TB disease was associated with a decreased risk of QFT-GIT reversion (OR: 0.4; 95% CI: 0.2, 1.0), and female sex was associated with a decreased risk of T-SPOT reversion (OR: 0.6; 95% CI: 0.4, 0.9). Reversion rates were lower for HCWs with higher baseline values for both IGRAs (Table 3) but remained over 50% in all strata for T-SPOT and those below 3.0 IU/ml for QFT-GIT.
The frequency of reversion of either IGRA test result was much higher among (Table E3 ). There were no differences in the magnitude of change from baseline to conversion between stable versus transient converters for either IGRA method.
Short-Term IGRA Variability
When tests were drawn 2 weeks apart ("repeatability" substudy), the results changed from negative to positive in 10 of 134 (7.5%) by QFT-GIT and 9 of 111 (8.1%) by T-SPOT. In addition, the results changed from positive to negative in 5 of 15 (33.3%) by QFT-GIT and 10 of 19 (52.6%) by T-SPOT. When two sets of tubes were filled during the same blood draw ("reproducibility"), there were discordant results (one positive and one negative test) in 10 of 172 (5.8%) by QFT-GIT and 10 of 153 (6.5%) by T-SPOT (P = 0.39).
Plasma samples from 114 individuals with a positive QFT-GIT and 187 with a negative QFT-GIT were retested by ELISA after a median of 8 days (IQR: 0-10 d) for the "rerun" substudy. All 187 negatives remained negative. Of the 114 positives, 27 (23.7%) were negative on rerun. This included 24 of 54 (44%) with no prior positive QFT-GIT (i.e., apparent new conversions that were more likely to be false positives) versus 3 of 60 (5.0%) who had a prior positive QFT-GIT and were therefore more likely to have a true TB infection. (Figure E1 ). Among 11 participants with a positive QFT-GIT at the impact time point, 10 (90.1%) had a quantitative decline in QFT-GIT at 6 months including 4 (36.4%) who became negative. Among 13 participants with a positive T-SPOT at the impact time point, 11 (84.6%) had a quantitative decline at 6 months including 9 (69.2%) who became negative or borderline ( Figure E1 ).
Assessment of Cumulative Conversions over 18 Months, Using Alternative Definitions
Given the unexpectedly high numbers of IGRA conversions when using the conventional cut points, we explored alternative definitions for a conversion (see the online supplement). For QFT-GIT, a cut point of 0.70 IU/ml reduced the proportion of converters to 53 of 2,263 (2.3%), which remained significantly higher (P , 0.001) than the proportion of TST conversions, 21 of 2,293 (0.9%). A cut point of 1.0 IU/ml reduced the QFT-GIT converters to 33 of 2,263 (1.5%; P = 0.09 vs. TST). For T-SPOT, a cut point of 10 spots reduced the proportion converting to 124 of 2,137 (5.8%; P , 0.001 vs. TST). Conversion cut points of 1.6 IU/ml for QFT-GIT and 21 spots for T-SPOT were required to reduce conversion rates to that of TST. 
Discussion
This study is, to our knowledge, the largest prospective comparison of TST, QFT-GIT, and T-SPOT performed at four time points in a cohort of HCWs with low risk for incident TB infection. Results from this multicenter study in more than 2,400 U.S. HCWs showed that among those routinely screened by occupational health programs, the baseline prevalence of positive tests was higher for QFT-GIT (3.8%) and T-SPOT (5.0%) than TST (1.8%), and that the cumulative test conversions over 18 months were 6 to 9 times higher. The proportions of TST converters observed during the study were similar to the proportions reported by each institution's occupational health testing program in recent prior years as detailed in the online supplement, and similar to those reported for U.S. healthcare institutions with effective TB control programs (5) . We conclude that a simultaneous increase in transmission of M. tuberculosis at the four institutions cannot account for the higher rate of positive IGRA results at baseline and follow-up.
Absence of a true gold standard test for LTBI presents a major challenge for determining the accuracy of new LTBI tests (10) . Therefore to assess the validity of the observed positive IGRA results, we explored epidemiologic factors, the quantitative and qualitative changes in IGRA results at follow-up and in the shortterm variability substudies, and the agreement (or lack thereof) between the results of the two IGRAs and TST done at the same time. The results of our study suggest that the majority of newly positive TSTs and IGRAs at baseline and follow-up in our population were due to false-positive tests. First, reversions for all three tests were observed in more than 50% of participants with a baseline positive test and at least one follow-up, most conversions occurred to only one of the three tests, none of the participants had a conversion on all three tests simultaneously, and only four participants converted by two tests. In addition, conversions were not associated with TB exposure risks, and more than 90% of TST converters who were retested and For QFT-GIT, 21 tests (0.9% of 2,418) were initially "failed," but for all specimens the enzyme-linked immunoassay was repeated using the existing stimulated plasma samples; all tests yielded a result on repeat testing: 18 of 21 were negative and 3 of 21 were positive.
ORIGINAL ARTICLE
75% of IGRA converters were negative on testing 6 months later without treatment.
Among participants who had an isolated positive IGRA at baseline, reversion rates were high, but rates were relatively low among the 30 triple-positive participants who were more likely to have true LTBI. The short-term variability substudies provide further support for interpreting the high IGRA conversion rates as falsepositive results. The frequency of negativeto-positive discordance between tests drawn 2 weeks apart and when two sets of tests were drawn simultaneously was, in both cases, more than 5% and was similar to the IGRA conversion rates during serial 6-month testing. Last, almost half of apparent new conversions by QFT-GIT were not confirmed when the same plasma sample was rerun by ELISA. These findings suggest that the IGRA specificity in U.S. HCWs at low risk for new TB infection is less than the specificity previously reported. Prior studies that estimated the specificity compared QFT-GIT or T-SPOT with TST at a single time point in young adults with no identified risk for TB exposure (28) (29) (30) (31) (32) (33) . A meta-analysis reported that QFT-GIT specificity was 99% (95% CI, 98-100%) based on 512 individuals from 5 studies, and T-SPOT specificity was 86% (95% CI, 81-90%) based on 255 individuals in 3 studies (34). Our study cohort included some individuals from high-prevalence countries, and thus the observed specificity would be expected to be lower than in studies that included only low-risk individuals.
We assessed whether any variables would allow us to differentiate between stable and transient conversions at the time of the result. Variables related to TB exposure and IGRA quantitative values were evaluated but none were helpful at the individual patient level. Overall, the inability to predict whether a conversion will be transient versus stable underscores the difficulty faced by clinicians and patients in assessing the future risk of TB disease, which is needed to balance the risks and benefits of LTBI treatment.
Possible reasons for short-and longterm variability with both IGRAs include factors that relate to the subject and those that relate to the laboratory. One possible explanation for the unexpectedly high proportions of IGRA conversions is that quantitatively small changes occurring around a fixed cut point could result in qualitative changes from negative to positive, termed the "wobble" effect. As has been observed by others (12, 15, 28, 29, 34) , we found that QFT-GIT variability and conversions were more likely to occur in individuals with initial values just below the cut point. The expected within-subject variability in the TB response of QFT-GIT has been reported to be 60.60 IU/ml when stimulated samples from the same patient are tested twice and can affect the qualitative result for tests near the cut point (35) . Some have suggested that the addition of a "borderline zone" for QFT-GIT similar to T-SPOT could help prevent misclassification of these individuals (36) . Although this is true, individuals with initial values close to the cut points represented only a small proportion (15-18%) of the overall converters in our study, and we do not believe the borderline zone is helpful clinically. Both intra-and interlaboratory variability was documented. Reasons for such variability include possible differences in laboratory procedures such as variation in processing, time to incubation, and incubation time (36, 37) . Although each laboratory followed standard practices and received training from the manufacturer of each test, there exists within these practices some room for variability that can affect results (38) .
Alternative definitions for classifying IGRA conversions were explored. As expected, raising the cut points and/or requiring a minimum quantitative change reduced the conversion rates for both IGRAs. However, the alternative definitions may increase the likelihood that some true infections will be missed. If one assumes the triple-positive participants at baseline have true LTBI, the sensitivity for detecting new TB infection based on obtaining positive results on repeat testing would be 91.5 and 85.2% for QFT-GIT and T-SPOT, respectively. Therefore the safety, effectiveness, and costeffectiveness of such strategies require careful assessment.
Absence of cross-reactivity with BCG is an advantage of IGRAs over TST (39) . In 2005, 15% of all U.S. HCWs were foreign-born with 75% originating from Latin America, Asia, and Africa, where BCG vaccination is routine (40) . In our study, almost two-thirds of individuals with a positive baseline TST were negative by both IGRAs; BCG vaccination was strongly associated with this pattern of test discordance, as has been reported by others (33, 41, 42) . Our results support a role for IGRAs in accurately determining TB infection status in BCG-vaccinated HCWs. With respect to the impact of TST on IGRAs, individuals with a positive TST were at risk for IGRA boosting. Our results are consistent with those of others (43) (44) (45) , and extend the current evidence base by showing that the boosting effect wanes within 6 months.
Strengths of our study include enrollment at four sites with relatively diverse populations, performance of serial testing with TST as well as both IGRAs that are currently being used in U.S. clinical laboratories, and low rates of loss to follow-up. Limitations of our study include the inability to generalize our findings to immunosuppressed populations or settings with higher rates of TB disease or infection. In addition, our results may not be generalizable in other settings such as Europe, where the rate of positivity to IGRAs is often lower than that of TST, possibly due to the use of a different tuberculin (RT23) and the fact that HCWs are more likely to have received one or more BCG vaccinations than in the United States (46) . Not all participants with a positive TST accepted a subsequent TST for safety reasons, and this limited our ability to definitively determine the natural history of a positive TST in the studied population. Also, TSTs were performed with TUBERSOL, and the TST results may differ with other forms of PPD. Active TB disease was not diagnosed in any participant during follow-up, and therefore we were unable to assess the potential ability of IGRAs to predict incipient TB disease.
Overall, our findings support a role for IGRAs in testing BCG-vaccinated HCWs at baseline. However, routine serial testing of HCWs at low risk for TB infection is likely to result in falsepositive conversions, which occur six to nine times more frequently with IGRAs than with TST and must be balanced against any logistical advantages from using IGRAs. These conclusions are limited to low-risk individuals and should not be extrapolated to the use of IGRAs in testing high-risk individuals such as those exposed to infectious TB. For institutions using IGRAs for serial testing of low-risk HCWs in the absence of a known TB exposure, we believe that repeat testing for new converters should be considered to identify false-positive results. Repeating the ELISA from stimulated plasmas for individuals with a new positive QFT-GIT may also prove useful for excluding individuals who are not infected with TB from further testing or unnecessary treatment.
The findings of this study also raise questions about the usefulness of routine serial testing of low-risk HCWs. Because the four urban healthcare facilities in this study regularly diagnose and treat patients with TB, these findings highlight the need for cost-effectiveness studies of the serial testing of HCWs in similar and even lower TB risk settings and should prompt reexamination of current HCW TB screening strategies in the United States. n Author disclosures are available with the text of this article at www.atsjournals.org.
